GB2134781A - Composition for the treatment of stasis leg ulcers - Google Patents

Composition for the treatment of stasis leg ulcers Download PDF

Info

Publication number
GB2134781A
GB2134781A GB08304150A GB8304150A GB2134781A GB 2134781 A GB2134781 A GB 2134781A GB 08304150 A GB08304150 A GB 08304150A GB 8304150 A GB8304150 A GB 8304150A GB 2134781 A GB2134781 A GB 2134781A
Authority
GB
United Kingdom
Prior art keywords
water
composition
film
ulcers
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08304150A
Other versions
GB8304150D0 (en
GB2134781B (en
Inventor
Martin Whitefield
Hyman Yarrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diomed Developments Ltd
Original Assignee
Diomed Developments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diomed Developments Ltd filed Critical Diomed Developments Ltd
Priority to GB08304150A priority Critical patent/GB2134781B/en
Publication of GB8304150D0 publication Critical patent/GB8304150D0/en
Publication of GB2134781A publication Critical patent/GB2134781A/en
Application granted granted Critical
Publication of GB2134781B publication Critical patent/GB2134781B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/442—Colorants, dyes

Abstract

Stasis leg ulcers are advantageously treated by topical application, with pressure bandaging, of a composition comprising a film- forming material such as methyl- cellulose, an acid such as lactic acid, an anti-bacterial agent such as Brilliant Green, and water.

Description

SPECIFICATION Composition for the treatment of stasis leg ulcers This invention relates to compositions useful in the treatment of stasis leg ulcers.
The most common form of chronic leg ulcers are stasis ulcers also known as varicose, venous gravitational or post-thrombotic ulcers. Such ulcers are associated with damage to the valves of the veins in the leg which cause the normal venous blood flow from the leg to be impaired.
Tissue anoxia results, and minor injury can then produce an ulcer which, because of the poor nutrition and anoxia of the tissue, is very slow to heal and may increase in size. Such ulcers are commonest in old people, and are aggravated by obesity and immobility. The standard treatment for such ulcers involves tight bandaging of the affected leg in order to improve the venous blood flow, and also elevation of the leg for prolonged periods to produce the same effect.
While such treatment is usually effective by itself, there is a need for immediate local treatment of stasis ulcers in order to minimise the risk of infection and promote the natural healing process.
The present invention provides a composition for topical application to stasis ulcers which promotes their healing to a remarkable extent.
The composition of the present invention comprises a water soluble non-toxic film forming material, a non-toxic water-soluble acid, a water soluble anti-bacterial agent, and water. Preferably the composition may contain a minor proportion of a secondary solvent such as alcohol and/or a dye to provide an immediate visual indication of where the composition has been applied.
Desirably also the composition should include a thickener to facilitate the easy application of a relatively large amount of the composition to the affected area.
When such a composition is applied to a stasis ulcer and the water and other solvent (if present) allowed to evaporate, a solid water-absorbent and antiseptic film is formed on the surface of the ulcer. This acts as a support for the subsequently applied pressure bandaging and maintains antiseptic conditions in the vicinity of the ulcer during healing. The cellular debris which may accumulate during healing of the ulcer adheres to the film and is easily removed when the dressing is changed. However, it is an important advantage of the new compositions that frequent changing is not required and the solid dried film may remain in place for as long as a week before changing becomes desirable.
The water soluble non-toxic acid is preferably lactic acid, but may be any physiologically acceptable a-hydroxy carboxylic acid providing the requisite low pH, preferably from 2.5 to 4.5, and non-irritant to the tissues. The water-soluble film-forming material preferably also acts as a thickener for the composition. It is preferably a water-soluble film-forming cellulose derivative such as methyl cellulose. The molecular weight of the material should be chosen so that a film of adequate strength is obtained.
The anti-bacterial agent is conveniently also the dye stuff. Brilliant Green, in particular as specified in the British Pharmacopea, has an appropriate colour and anti-bacterial activity and is preferred.
It is generally desirable to include in the new compositions a small proportion of a non-toxic water-miscible solvent in order to promote the dissolution of the various ingredients. Ethyl alcohol is preferred for this purpose, but it will be understood that too high a proportion of ethyl alcohol is likely to cause irritation to the tissues.
Preferred compositions in accordance with the present invention thus comprise 1 to 5 parts by weight of methyl cellulose, 0.1 to 1 part by weight of lactic acid, 0.1 to 5 parts by weight of Brilliant Green, 1 to 10 parts by weight of ethyl alcohol with the balance to 100 parts by weight being formed of purified water. The ethyl alcohol is conveniently added in the form of industrial methylated spirit which contains a minor proportion of water.
The following Example illustrates the present invention.
Example parts by weight Brilliant Green 0.5 Lactic Acid 0.5 Methyl Cellulose 3.0 (MW=1 0,00) Ethyl alcohol (as Industrial Methylated Spirit) 5.0 Purified Water to 100.0 The Brilliant Green, lactic acid and methyl cellulose are dissolved in the water in the presence of the ethyl alcohol. A semi-solid viscous green gel is obtained.
This gel may be applied to a stasis ulcer and then allowed to dry when it forms a solid film which takes the shape of the lesion, which may then be covered with a dry sterile dressing or pad and then bandaged in the usual way. The solid film absorbs exudation from the ulcer and remains as a support for the pressure bandaging. It has anti-bacterial properties which reduce or eliminate the risk of infection. The film may be left in place for up to a week, and when removed, it assists in the removal of cellular debris and cleaning of the ulcerated area. The healing process is thus substantially accelerated.
Claims
1. A composition for topical application to stasis ulcers comprising a water-soluble, nontoxic, film-forming material, a non-toxic, watersoluble acid, a water-soluble anti-bacterial agent, and water.
**WARNING** end of DESC field may overlap start of CLMS **.

Claims (11)

**WARNING** start of CLMS field may overlap end of DESC **. SPECIFICATION Composition for the treatment of stasis leg ulcers This invention relates to compositions useful in the treatment of stasis leg ulcers. The most common form of chronic leg ulcers are stasis ulcers also known as varicose, venous gravitational or post-thrombotic ulcers. Such ulcers are associated with damage to the valves of the veins in the leg which cause the normal venous blood flow from the leg to be impaired. Tissue anoxia results, and minor injury can then produce an ulcer which, because of the poor nutrition and anoxia of the tissue, is very slow to heal and may increase in size. Such ulcers are commonest in old people, and are aggravated by obesity and immobility. The standard treatment for such ulcers involves tight bandaging of the affected leg in order to improve the venous blood flow, and also elevation of the leg for prolonged periods to produce the same effect. While such treatment is usually effective by itself, there is a need for immediate local treatment of stasis ulcers in order to minimise the risk of infection and promote the natural healing process. The present invention provides a composition for topical application to stasis ulcers which promotes their healing to a remarkable extent. The composition of the present invention comprises a water soluble non-toxic film forming material, a non-toxic water-soluble acid, a water soluble anti-bacterial agent, and water. Preferably the composition may contain a minor proportion of a secondary solvent such as alcohol and/or a dye to provide an immediate visual indication of where the composition has been applied. Desirably also the composition should include a thickener to facilitate the easy application of a relatively large amount of the composition to the affected area. When such a composition is applied to a stasis ulcer and the water and other solvent (if present) allowed to evaporate, a solid water-absorbent and antiseptic film is formed on the surface of the ulcer. This acts as a support for the subsequently applied pressure bandaging and maintains antiseptic conditions in the vicinity of the ulcer during healing. The cellular debris which may accumulate during healing of the ulcer adheres to the film and is easily removed when the dressing is changed. However, it is an important advantage of the new compositions that frequent changing is not required and the solid dried film may remain in place for as long as a week before changing becomes desirable. The water soluble non-toxic acid is preferably lactic acid, but may be any physiologically acceptable a-hydroxy carboxylic acid providing the requisite low pH, preferably from 2.5 to 4.5, and non-irritant to the tissues. The water-soluble film-forming material preferably also acts as a thickener for the composition. It is preferably a water-soluble film-forming cellulose derivative such as methyl cellulose. The molecular weight of the material should be chosen so that a film of adequate strength is obtained. The anti-bacterial agent is conveniently also the dye stuff. Brilliant Green, in particular as specified in the British Pharmacopea, has an appropriate colour and anti-bacterial activity and is preferred. It is generally desirable to include in the new compositions a small proportion of a non-toxic water-miscible solvent in order to promote the dissolution of the various ingredients. Ethyl alcohol is preferred for this purpose, but it will be understood that too high a proportion of ethyl alcohol is likely to cause irritation to the tissues. Preferred compositions in accordance with the present invention thus comprise 1 to 5 parts by weight of methyl cellulose, 0.1 to 1 part by weight of lactic acid, 0.1 to 5 parts by weight of Brilliant Green, 1 to 10 parts by weight of ethyl alcohol with the balance to 100 parts by weight being formed of purified water. The ethyl alcohol is conveniently added in the form of industrial methylated spirit which contains a minor proportion of water. The following Example illustrates the present invention. Example parts by weight Brilliant Green 0.5 Lactic Acid 0.5 Methyl Cellulose 3.0 (MW=1 0,00) Ethyl alcohol (as Industrial Methylated Spirit) 5.0 Purified Water to 100.0 The Brilliant Green, lactic acid and methyl cellulose are dissolved in the water in the presence of the ethyl alcohol. A semi-solid viscous green gel is obtained. This gel may be applied to a stasis ulcer and then allowed to dry when it forms a solid film which takes the shape of the lesion, which may then be covered with a dry sterile dressing or pad and then bandaged in the usual way. The solid film absorbs exudation from the ulcer and remains as a support for the pressure bandaging. It has anti-bacterial properties which reduce or eliminate the risk of infection. The film may be left in place for up to a week, and when removed, it assists in the removal of cellular debris and cleaning of the ulcerated area. The healing process is thus substantially accelerated. Claims
1. A composition for topical application to stasis ulcers comprising a water-soluble, nontoxic, film-forming material, a non-toxic, watersoluble acid, a water-soluble anti-bacterial agent, and water.
2. A composition according to claim 1 in which the said acid is an a-hydroxy-carboxylic acid and the composition contains sufficient of the said acid to provide a pH of 2.5 to 4.5.
3. A composition according to claim 2 in which the said acid is lactic acid.
4. A composition according to any one of claims 1 to 3 in which the film-forming material is a cellulose derivative.
5. A composition according to claim 4 in which the film-forming material is methyl-cellulose.
6. A composition according to any one of claims 1 to 5 in which the anti-bacterial agent is also a dyestuff.
7. A composition according to claim 6 in which the anti-bacterial agent is Brilliant Green.
8. A composition according to any one of claims 1 to 7 which also contains alcohol as a secondary solvent.
9. A composition according to claim 1 comprising 1 to 5 parts by weight of methylcellulose, 0.1 to 1 part by weight of lactic acid, 0.1 to 5 parts by weight of Brilliant Green, 1 to 10 parts by weight of ethyl alcohol, and the balance to 100 parts by weight of purified water.
10. A composition according to claim 1 substantially as described in the Example.
11. A composition as claimed in any one of claims 1 to 10 for use in therapy in the treatment of stasis ulcers.
GB08304150A 1983-02-15 1983-02-15 Composition for the treatment of stasis leg ulcers Expired GB2134781B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB08304150A GB2134781B (en) 1983-02-15 1983-02-15 Composition for the treatment of stasis leg ulcers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08304150A GB2134781B (en) 1983-02-15 1983-02-15 Composition for the treatment of stasis leg ulcers

Publications (3)

Publication Number Publication Date
GB8304150D0 GB8304150D0 (en) 1983-03-16
GB2134781A true GB2134781A (en) 1984-08-22
GB2134781B GB2134781B (en) 1986-02-12

Family

ID=10538021

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08304150A Expired GB2134781B (en) 1983-02-15 1983-02-15 Composition for the treatment of stasis leg ulcers

Country Status (1)

Country Link
GB (1) GB2134781B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005391A1 (en) * 1985-03-13 1986-09-25 Gluck Bruno A Antiseptic fluids
WO1993013763A1 (en) * 1992-01-21 1993-07-22 Howard Alliger Method of treating small mouth ulcers
EP0576753A1 (en) * 1986-06-24 1994-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Devices for carrying out a plurality of microbiological tests
US5531726A (en) * 1993-09-21 1996-07-02 Johnson & Johnson, Inc. Sphagnum moss composition for the production of sheeted absorbent and method for evaluating the potential of sphagnum moss material for absorbing liquid
WO2001000023A1 (en) * 1999-06-29 2001-01-04 The Procter & Gamble Company Tissue products having antiviral properties
US6517849B1 (en) 1999-10-19 2003-02-11 The Procter & Gamble Company Tissue products containing antiviral agents which are mild to the skin
GB2402882A (en) * 2003-06-20 2004-12-22 Johnson & Johnson Medical Ltd Bioabsorbable wound dressing containing an antioxidant dye
WO2006088342A1 (en) * 2005-02-18 2006-08-24 Inga Lyashenko Textile article for therapeutic use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1213295A (en) * 1967-04-27 1970-11-25 Boots Pure Drug Co Ltd Improvements in therapeutic compositions for topical application

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1213295A (en) * 1967-04-27 1970-11-25 Boots Pure Drug Co Ltd Improvements in therapeutic compositions for topical application

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005391A1 (en) * 1985-03-13 1986-09-25 Gluck Bruno A Antiseptic fluids
EP0576753A1 (en) * 1986-06-24 1994-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Devices for carrying out a plurality of microbiological tests
WO1993013763A1 (en) * 1992-01-21 1993-07-22 Howard Alliger Method of treating small mouth ulcers
US5389679A (en) * 1992-01-21 1995-02-14 Alliger; Howard Method of treating small mouth ulcers with lactic acid
US5516799A (en) * 1992-01-21 1996-05-14 Alliger; Howard M. Method of treating small mouth ulcers
US5731347A (en) * 1992-01-21 1998-03-24 Alliger; Howard M. Method of treating small mouth ulcers
US5531726A (en) * 1993-09-21 1996-07-02 Johnson & Johnson, Inc. Sphagnum moss composition for the production of sheeted absorbent and method for evaluating the potential of sphagnum moss material for absorbing liquid
WO2001000023A1 (en) * 1999-06-29 2001-01-04 The Procter & Gamble Company Tissue products having antiviral properties
US6517849B1 (en) 1999-10-19 2003-02-11 The Procter & Gamble Company Tissue products containing antiviral agents which are mild to the skin
GB2402882A (en) * 2003-06-20 2004-12-22 Johnson & Johnson Medical Ltd Bioabsorbable wound dressing containing an antioxidant dye
GB2402882B (en) * 2003-06-20 2007-03-28 Johnson & Johnson Medical Ltd Antioxidant wound dressing materials
WO2006088342A1 (en) * 2005-02-18 2006-08-24 Inga Lyashenko Textile article for therapeutic use

Also Published As

Publication number Publication date
GB8304150D0 (en) 1983-03-16
GB2134781B (en) 1986-02-12

Similar Documents

Publication Publication Date Title
AU716244B2 (en) Sterilisable paste product for topical application
US5902600A (en) Hydrogel polymer wound dressing
JP3485593B2 (en) Hydrocolloid gel for wound
JP2617260B2 (en) Gel composition for wound treatment
US3969498A (en) Dressing and method for treating a wound
KR100847971B1 (en) A wound-healing dressing patch with hydrogel layer containing chitosan
US2832343A (en) Dilators
JP3000104B2 (en) Compositions and methods for forming a film at native sites on body tissue
KR960003732A (en) Sterile Gel Compositions for Wound Care
DE3856018D1 (en) Use of a disaccharide polysulfate-aluminum compound for the manufacture of a medicament for the treatment of HÄMORRHOIDEN and for wound healing
FI102725B1 (en) Crosslinked hydrogel that absorbs wound secretions
GB2134781A (en) Composition for the treatment of stasis leg ulcers
NO168342C (en) PROCEDURE FOR PREPARING A SALVE
TW201217005A (en) Method of hydrogel sheet for wound
HU200103B (en) Process for producing pharmaceutical compositions for treating lack of epithelium
Yadav et al. Topical phenytoin in the treatment of split-thickness skin autograft donor sites: a comparative study with polyurethane membrane drape and conventional dressing
AU612387B2 (en) Pharmaceutical compositions promoting the wound healing and process for preparing same
IE55501B1 (en) Composition for the treatment of wounds
JP6026540B2 (en) Composition for the treatment of peripheral ulcers of various causes
US5906601A (en) Use of an adhesive composition in the manufacture of a wound dressing
CA2404210C (en) Pharmaceutical gel composition
JP2003128557A (en) Glucosamine-containing cataplasm
Friedman et al. Care of the split-thickness skin graft donor site
US5616619A (en) Topical composition for burn relief and method of use
RU2165754C2 (en) Ointment for treatment of suppurative-inflammatory diseases, burns, articulation inflammatory diseases, trophic ulcers and sluggish wounds, method of its preparing and method of treatment

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19950215